Search

European Hematology Association tentatively responds to the European Commission’s proposal to improve clinical research

In addition, the regulation appears to accommodate multi-national trials with, for instance, a harmonized authorization dossier, and a single submission system.

Read more

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.

Read more

Nominate yourself

You can nominate yourself for an EHA Board role as long as you have:

Any type of EHA membership apart from healthcare-affiliated membership
Paid your annual membership fees
If you're unsure how to pay your annual membership fees, visit our renew your membership…

Read more

EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials

EHA has responded to the EMA’s call for comments on the reflection paper on February 15.

Read more

Meeting program

Friday, April 25 - EHA-Balkan Hematology Day 202509:00 - 10:10 CEST Opening remarks & special lecture

Welcome of participants
Dimitar Efremov (Italy)
Welcome and introduction of meeting program
Irina Panovska-Stavridis (North Macedonia)
EHA and History of Balkan Hematology Day
Gianluca Gaidano (Italy)
History of the Balkan Hematology…

Read more

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Read more

EHA-Baltic Hematology Tutorial in Estonia provides European-level expertise to local hematologists

EHA partnered with three Baltic societies on October 18 and 19 to provide European-level expertise to local hematology trainees and experienced hematologists.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more